In this issue:
Zanubrutinib for CLL/SLL
Risk of CVD death among Hodgkin lymphoma survivors
Lenalidomide + R-GDP in R/R DLBCL
RT for early-stage, low-risk paediatric Hodgkin lymphoma
Etoposide + ASCT for stage II-IV PTCL
Bendamustine + rituximab in transplant-eligible MCL
Rituximab + LMB-based chemotherapy in children with PMLBCL
Acalabrutinib for R/R MZL
Selinexor + chemo for elderly AML and high risk MDS
Characteristics, prognostic indicators, and outcomes for IVL
Please login below to download this issue (PDF)